ConjuChem Inc (CJB-T) Stock Predictions - Stockchase
WATCH LIST
23
ConjuChem Inc (CJB-T)

ON STOCKCHASE SINCE Jun 2003

biotechnology/pharmaceutical

ConjuChem Inc

CJB-T

0 watching          
Join the Discussion

ConjuChem Inc (CJB-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about CJB-T



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
ConjuChem Inc(CJB-T) 

November 26, 2007

Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$0.130
Owned Owned
No

DON'T BUY
ConjuChem Inc(CJB-T) 

April 7, 2005

Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$3.750
Owned Owned
No

WEAK BUY
ConjuChem Inc(CJB-T) 

February 7, 2005

Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$4.700
Owned Owned
No

WAIT
ConjuChem Inc(CJB-T) 

January 6, 2005

Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Werner Muehelem

Vice Presi, ING Funds...

Price Price
$4.910
Owned Owned
No

DON'T BUY
ConjuChem Inc(CJB-T) 

November 4, 2004

The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$3.490
Owned Owned
No

WAIT
ConjuChem Inc(CJB-T) 

September 24, 2004

Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$2.800
Owned Owned
No

DON'T BUY
ConjuChem Inc(CJB-T) 

September 8, 2004

The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Andrew McCreath

Senior Por, Sentry Select Capita...

Price Price
$3.400
Owned Owned
No

WEAK BUY
ConjuChem Inc(CJB-T) 

August 23, 2004

Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Martin Hubbes,

Executive , AGF Funds Inc....

Price Price
$3.990
Owned Owned
Yes

DON'T BUY
ConjuChem Inc(CJB-T) 

August 6, 2004

Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President, Campbell and Lee Inv...

Price Price
$3.610
Owned Owned
No

TOP PICK
ConjuChem Inc(CJB-T) 

July 30, 2004

Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ed Ho

Portfolio , Dynamic Mutual Funds...

Price Price
$3.990
Owned Owned
Yes

DON'T BUY
ConjuChem Inc(CJB-T) 

July 28, 2004

Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$4.270
Owned Owned
Yes

DON'T BUY
ConjuChem Inc(CJB-T) 

July 15, 2004

A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$4.800
Owned Owned
No

BUY
ConjuChem Inc(CJB-T) 

July 8, 2004

An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$11.500
Owned Owned
Yes

BUY
ConjuChem Inc(CJB-T) 

May 12, 2004

Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$11.720
Owned Owned
Yes

DON'T BUY
ConjuChem Inc(CJB-T) 

April 22, 2004

Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Glenn Paradis,

Vice Presi, Aegon Capital Manage...

Price Price
$13.800
Owned Owned
No

Showing 1 to 15 of 23 entries
Successfully Saved Company
Successfully Saved Company
0+
JOIN THE DISCUSSION
0 comments in the last 7 days